Journal ArticleDOI
Immunogenic cancer cell death: a key-lock paradigm.
Antoine Tesniere,Lionel Apetoh,Lionel Apetoh,Lionel Apetoh,François Ghiringhelli,François Ghiringhelli,François Ghiringhelli,Nicholas Joza,Nicholas Joza,Nicholas Joza,Theocharis Panaretakis,Theocharis Panaretakis,Theocharis Panaretakis,Oliver Kepp,Oliver Kepp,Oliver Kepp,Frédéric Schlemmer,Frédéric Schlemmer,Frédéric Schlemmer,Laurence Zitvogel,Laurence Zitvogel,Laurence Zitvogel,Guido Kroemer,Guido Kroemer,Guido Kroemer +24 more
TLDR
The concept that immunogenic death involves changes in the composition of the cell surface, as well as the release of soluble immunogenic signals that occur in a defined temporal sequence is discussed.About:
This article is published in Current Opinion in Immunology.The article was published on 2008-10-01. It has received 306 citations till now. The article focuses on the topics: Immunogenic cell death & Immune system.read more
Citations
More filters
Journal ArticleDOI
Immunogenic Cell Death in Cancer Therapy
TL;DR: It is postulate that ICD constitutes a prominent pathway for the activation of the immune system against cancer, which in turn determines the long-term success of anticancer therapies and its subversion by pathogens.
Journal ArticleDOI
Cancer immunotherapy via dendritic cells
TL;DR: Dendritic cells are an essential target in efforts to generate therapeutic immunity against cancer owing to their ability to control both immune tolerance and immunity.
Journal ArticleDOI
Immune infiltration in human tumors: a prognostic factor that should not be ignored.
Franck Pagès,Jérôme Galon,Jérôme Galon,Jérôme Galon,Marie-Caroline Dieu-Nosjean,Marie-Caroline Dieu-Nosjean,Marie-Caroline Dieu-Nosjean,Eric Tartour,Catherine Sautès-Fridman,Catherine Sautès-Fridman,Catherine Sautès-Fridman,Wolf H. Fridman +11 more
TL;DR: An immune scoring based on the type, density and location of lymphocyte infiltrates as a novel prognostic factor for use in addition to tumor node metastasis staging to predict disease-free survival and to aid in decisions regarding adjuvant therapies in early stage human cancers.
Journal ArticleDOI
Immunogenic death of colon cancer cells treated with oxaliplatin.
Antoine Tesniere,Frédéric Schlemmer,Frédéric Schlemmer,Frédéric Schlemmer,Valérie Boige,Oliver Kepp,Oliver Kepp,Oliver Kepp,Isabelle Martins,Isabelle Martins,Isabelle Martins,François Ghiringhelli,Laetitia Aymeric,Laetitia Aymeric,Laetitia Aymeric,Mickaël Michaud,Mickaël Michaud,Mickaël Michaud,Lionel Apetoh,Lionel Apetoh,Lionel Apetoh,Ludovic Barault,Jean Mendiboure,J.-P. Pignon,Valérie Jooste,P van Endert,Michel Ducreux,Michel Ducreux,Laurence Zitvogel,F. Piard,Guido Kroemer,Guido Kroemer,Guido Kroemer +32 more
TL;DR: OXP induces immunogenic death of CRC cells, and this effect determines its therapeutic efficacy in CRC patients, and both oxaliplatin and cisplatin were equally efficient in triggering HMGB1 release.
Journal ArticleDOI
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
Thomas J. Lynch,Igor Bondarenko,Alexander Luft,Piotr Serwatowski,Fabrice Barlesi,Raju Titus Chacko,Martin Sebastian,Joel W. Neal,Haolan Lu,Jean-Marie Cuillerot,Martin Reck +10 more
TL;DR: Phased ipilimumab plus paclitaxel and carboplatin improved irPFS and PFS, which supports additional investigation of ipil optimumab in NSCLC.
References
More filters
Journal ArticleDOI
The biochemistry of apoptosis
TL;DR: The basic components of the death machinery are reviewed, how they interact to regulate apoptosis in a coordinated manner is described, and the main pathways that are used to activate cell death are discussed.
Journal ArticleDOI
Release of chromatin protein HMGB1 by necrotic cells triggers inflammation
TL;DR: It is reported that Hmgb1-/- necrotic cells have a greatly reduced ability to promote inflammation, which proves that the release of HMGB1 can signal the demise of a cell to its neighbours, and cells undergoing apoptosis are programmed to withhold the signal that is broadcast by cells that have been damaged or killed by trauma.
Journal ArticleDOI
Classification of cell death: recommendations of the Nomenclature Committee on Cell Death
Guido Kroemer,Guido Kroemer,Guido Kroemer,Lorenzo Galluzzi,Lorenzo Galluzzi,Lorenzo Galluzzi,Peter Vandenabeele,John M. Abrams,Emad S. Alnemri,Eric H. Baehrecke,Mikhail V. Blagosklonny,Wafik S. El-Deiry,Pierre Golstein,Pierre Golstein,Douglas R. Green,Michael O. Hengartner,Richard A. Knight,Sharad Kumar,Stuart A. Lipton,Stuart A. Lipton,Stuart A. Lipton,Walter Malorni,Gabriel Núñez,Marcus E. Peter,Juerg Tschopp,Junying Yuan,Mauro Piacentini,Boris Zhivotovsky,Gerry Melino,Gerry Melino +29 more
TL;DR: This study details the 2009 recommendations of the NCCD on the use of cell death-related terminology including ‘entosis’, ‘mitotic catastrophe”,’ ‘necrosis‚ ‘necroptosis‚’ and ‘pyroptotic’.
Journal ArticleDOI
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.
Lionel Apetoh,François Ghiringhelli,Antoine Tesniere,Antoine Tesniere,Antoine Tesniere,Michel Obeid,Michel Obeid,Michel Obeid,Carla Ortiz,Carla Ortiz,Carla Ortiz,Alfredo Criollo,Alfredo Criollo,Alfredo Criollo,Grégoire Mignot,Grégoire Mignot,Grégoire Mignot,M. Chiara Maiuri,Evelyn Ullrich,Evelyn Ullrich,Evelyn Ullrich,Patrick Saulnier,Huan Yang,Sebastian Amigorena,Bernard Ryffel,Franck J. Barrat,Paul Saftig,Francis Lévi,Francis Lévi,Rosette Lidereau,Catherine Noguès,Jean-Paul Mira,Agnès Chompret,Virginie Joulin,Françoise Clavel-Chapelon,Jean Bourhis,Fabrice Andre,Suzette Delaloge,T. Tursz,Guido Kroemer,Guido Kroemer,Guido Kroemer,Laurence Zitvogel +42 more
TL;DR: A previously unrecognized pathway for the activation of tumor antigen–specific T-cell immunity that involves secretion of the high-mobility-group box 1 (HMGB1) alarmin protein by dying tumor cells and the action of HMGB1 on Toll-like receptor 4 (TLR4) expressed by dendritic cells (DCs) is described.
Journal ArticleDOI
Calreticulin exposure dictates the immunogenicity of cancer cell death
Michel Obeid,Antoine Tesniere,Antoine Tesniere,Antoine Tesniere,François Ghiringhelli,François Ghiringhelli,François Ghiringhelli,Gian Maria Fimia,Lionel Apetoh,Lionel Apetoh,Lionel Apetoh,Jean-Luc Perfettini,Jean-Luc Perfettini,Jean-Luc Perfettini,Maria Castedo,Maria Castedo,Maria Castedo,Grégoire Mignot,Grégoire Mignot,Grégoire Mignot,Theoharis Panaretakis,Theoharis Panaretakis,Theoharis Panaretakis,Noelia Casares,Noelia Casares,Noelia Casares,Didier Métivier,Didier Métivier,Didier Métivier,Nathanael Larochette,Nathanael Larochette,Nathanael Larochette,Peter van Endert,Peter van Endert,Fabiola Ciccosanti,Mauro Piacentini,Laurence Zitvogel,Laurence Zitvogel,Laurence Zitvogel,Guido Kroemer,Guido Kroemer,Guido Kroemer +41 more
TL;DR: It is shown that anthracyclin-induced CRT translocation induces the rapid, preapoptotic translocation of calreticulin (CRT) to the cell surface and is identified as a key feature determining anticancer immune responses.
Related Papers (5)
Calreticulin exposure dictates the immunogenicity of cancer cell death
Michel Obeid,Antoine Tesniere,Antoine Tesniere,Antoine Tesniere,François Ghiringhelli,François Ghiringhelli,François Ghiringhelli,Gian Maria Fimia,Lionel Apetoh,Lionel Apetoh,Lionel Apetoh,Jean-Luc Perfettini,Jean-Luc Perfettini,Jean-Luc Perfettini,Maria Castedo,Maria Castedo,Maria Castedo,Grégoire Mignot,Grégoire Mignot,Grégoire Mignot,Theoharis Panaretakis,Theoharis Panaretakis,Theoharis Panaretakis,Noelia Casares,Noelia Casares,Noelia Casares,Didier Métivier,Didier Métivier,Didier Métivier,Nathanael Larochette,Nathanael Larochette,Nathanael Larochette,Peter van Endert,Peter van Endert,Fabiola Ciccosanti,Mauro Piacentini,Laurence Zitvogel,Laurence Zitvogel,Laurence Zitvogel,Guido Kroemer,Guido Kroemer,Guido Kroemer +41 more
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.
Lionel Apetoh,François Ghiringhelli,Antoine Tesniere,Antoine Tesniere,Antoine Tesniere,Michel Obeid,Michel Obeid,Michel Obeid,Carla Ortiz,Carla Ortiz,Carla Ortiz,Alfredo Criollo,Alfredo Criollo,Alfredo Criollo,Grégoire Mignot,Grégoire Mignot,Grégoire Mignot,M. Chiara Maiuri,Evelyn Ullrich,Evelyn Ullrich,Evelyn Ullrich,Patrick Saulnier,Huan Yang,Sebastian Amigorena,Bernard Ryffel,Franck J. Barrat,Paul Saftig,Francis Lévi,Francis Lévi,Rosette Lidereau,Catherine Noguès,Jean-Paul Mira,Agnès Chompret,Virginie Joulin,Françoise Clavel-Chapelon,Jean Bourhis,Fabrice Andre,Suzette Delaloge,T. Tursz,Guido Kroemer,Guido Kroemer,Guido Kroemer,Laurence Zitvogel +42 more
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors
François Ghiringhelli,Lionel Apetoh,Antoine Tesniere,Antoine Tesniere,Antoine Tesniere,Laetitia Aymeric,Laetitia Aymeric,Laetitia Aymeric,Yuting Ma,Yuting Ma,Yuting Ma,Carla Ortiz,Karim Vermaelen,Theocharis Panaretakis,Theocharis Panaretakis,Theocharis Panaretakis,Grégoire Mignot,Evelyn Ullrich,Evelyn Ullrich,Evelyn Ullrich,Jean-Luc Perfettini,Jean-Luc Perfettini,Jean-Luc Perfettini,Frédéric Schlemmer,Frédéric Schlemmer,Frédéric Schlemmer,Ezgi Tasdemir,Ezgi Tasdemir,Ezgi Tasdemir,Martin Uhl,Pierre Génin,Ahmet Civas,Bernhard Ryffel,Jean Kanellopoulos,Jürg Tschopp,Fabrice Andre,Fabrice Andre,Fabrice Andre,Rosette Lidereau,Nicole McLaughlin,Nicole M. Haynes,Mark J. Smyth,Guido Kroemer,Guido Kroemer,Guido Kroemer,Laurence Zitvogel +45 more
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.
F. Stephen Hodi,Steven J. O'Day,David F. McDermott,R. W. Weber,Jeffrey A. Sosman,John B. A. G. Haanen,Rene Gonzalez,Caroline Robert,Dirk Schadendorf,Jessica C. Hassel,Wallace Akerley,Alfons J.M. van den Eertwegh,Jose Lutzky,Paul Lorigan,Julia Vaubel,Gerald P. Linette,David W. Hogg,Christian H. Ottensmeier,Céleste Lebbé,Christian Peschel,Ian Quirt,Joseph I. Clark,Jedd D. Wolchok,Jeffrey S. Weber,Jason Tian,Michael Yellin,Geoffrey M. Nichol,Axel Hoos,Walter J. Urba +28 more